Table 1 |
|||
|
Analysis of Genotype and Allele frequencies of the BAT1 -22, TNFA -308 and TNFA -850 polymorphisms |
|||
| Marker |
Genotype or allele |
Ctrl numbers (%) |
AD numbers (%) |
|
|
|||
| BAT1 -22 |
1/1 |
144 (40.1) |
117 (43.0) |
| 1/2 |
167 (46.5) |
138 (50.7) |
|
| 2/2 |
48 (13.4) |
17 (6.3)a |
|
| 1 |
455 (63.4) |
372 (68.4) |
|
| 2 |
263 (36.6) |
172 (31.6) |
|
| TNFA -308 |
1/1 |
226 (63.0) |
188 (69.1) |
| 1/2 |
104 (29.0) |
70 (25.7) |
|
| 2/2 |
29 (8.0) |
14 (5.1) |
|
| 1 |
556 (77.4) |
446 (82.0) |
|
| 2 |
162 (22.6) |
98 (18.0)b |
|
| TNFA -850 |
1/1 |
287 (79.9) |
183 (67.3) |
| 1/2 |
61 (17.0) |
70 (25.7) |
|
| 2/2 |
11 (3.1) |
19 (7.0)c |
|
| 1 |
635 (88.4) |
436 (80.1) |
|
| 2 |
83 (11.6) |
108 (19.9)d |
|
|
Ctrl = Control cases without AD pathology AD = Alzheimer's disease cases a BAT1 -22*2/2 versus non-2/2 in AD, P < .005 (Pearson χ2 = 8.49) OR = 0.43 (95% CI = 0.24 – 0.77). b TNFA -308*2 allele in AD, P = .048 (Pearson χ2 = 3.91) OR = 0.75 (95% CI = 0.57 – 1.00). c TNFA -850*(2/2, 1/2) versus 1/1 in AD, P < .001 (Pearson χ2 = 13.06) OR = 1.94 (95% CI = 1.35 – 2.78.0). d TNFA -850*2 allele in AD, P < .001 (Pearson χ2 = 16.57) OR = 1.90 (95% CI = 1.39 – 2.59). | |||
Gnjec et al. Journal of Neuroinflammation 2008 5:36 doi:10.1186/1742-2094-5-36 |
|||
